Compare Amgen, Inc. (AMGN) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs LYFT Inc — how do they compare? Amgen, Inc. trades at $362.06 (market cap $196.12B), while LYFT Inc trades at $15.87 (market cap $5.93B). The key difference: Amgen, Inc. is far larger — about 33.1× LYFT Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while LYFT Inc pays none. Which is the better fit depends on your goals.
| AMGN | LYFT | |
|---|---|---|
Market Cap | $196.12B | $5.93B |
Sector | Health | Industrials |
52-Week High | $388.16 | $24.57 |
52-Week Low | $271.18 | $12.65 |
Enterprise Value | $241.41B | $5.46B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Lyft trades at $15.61, down 0.83% on the day, with a bullish technical signal from moving averages and key indicators like ADX. The company shows strong profitability with a net income margin of 43.82% and robust cash flow of $891M in 2025. Recent news highlights expansion into Europe and autonomous vehicle partnerships, while analyst consensus is mixed with a $18.25 price target.
Lyft presents an attractive valuation with a P/E of 2.28 and P/S of 0.99, but faces risks from competitive pressures and inconsistent earnings beats. The stock's upside potential hinges on execution of growth initiatives, though regulatory concerns and market volatility remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
